¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement inactivation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® complement ÇÑ±Û º¸Ã¼
¼³¸í   
  Ç×ü¿Í ¹ÝÀÀÇÏ¿© Ç×ü¿Í °áÇյȠ¼¼Æ÷ÀÇ ÆÄ±«¸¦ ÀÏÀ¸Å°´Â ´Ü¹éÁúÀ» ¸»ÇÑ´Ù. Ç×ü°¡ Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ Àִµ¥ ±× ÁßÀÇ Çϳª·Î Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷ÀǠǥ¸éÀ» ºÎºÐÀûÀ¸·Î ¼Õ»ó½ÃÄÑ ±× ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¿ªÇÒÀ» Çϴ °ÍÀÌ ÀÌ º¸Ã¼ÀÌ´Ù. º¸Ã¼´Â 20°¡ÁöÀÇ ´Ü¹éÁú·Î ±¸¼ºµÇ¾î Àִµ¥ ¾àÀڷΠC·Î Ç¥½ÃÇϸ砰¢ Á¾·ù¸¦ ³ªÅ¸³¾ °æ¿ì¿¡´Â C¿·¿¡ ¼ýÀÚ¸¦ ½á¼­ Ç¥½ÃÇÑ´Ù.
¿µ¹® complement fixation reaction ÇÑ±Û º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¼³¸í   
  Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ À־ º¸Ã¼¿Í °áÇÕÇϴ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼­´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇϴ ¿ëÇ÷¼ÒÀǠȥÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀϾ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼­ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉí, Å¬¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heat inactivation
    ¿­ºÒȰ¼ºÈ­
  • inactivation
    ºÒȰ¼ºÈ­, ºñȰ¼ºÈ­
  • insertional inactivation
    »ðÀÔÀ¯ÀüÀÚºñȰ¼ºÈ­
  • photodynamic inactivation
    ±¤¿ªÇкÒȰ¼ºÈ­
  • X inactivation
    XºÒȰ¼ºÈ­
  • alternative complement pathway
    ´ëüº¸Ã¼°æ·Î
  • classic complement pathway
    ÀüÇüÀûº¸Ã¼°æ·Î
  • complement
    º¸Ã¼, µµ¿òü
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • complement cascade
    º¸Ã¼¿¬¼â¹ÝÀÀ, µµ¿òü¿¬¼â¹ÝÀÀ
  • complement component
    º¸Ã¼¼ººÐ, µµ¿òü¼ººÐ
  • complement fixation
    º¸Ã¼°áÇÕ
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ
  • complement fixation test
    º¸Ã¼°áÇÕ°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    µµ¿òü, º¸Ã¼
  • complement cascade
    µµ¿òü¿¬¼â¹ÝÀÀ, º¸Ã¼¿¬¼â¹ÝÀÀ
  • complement fixation reaction
    µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heat inactivation
    ¿­ºÒȰ¼ºÈ­
  • inactivation
    ºÒȰ¼º
  • insertional inactivation
    »ðÀÔÀ¯ÀüÀÚºñȰ¼º
  • photodynamic inactivation
    ±¤¿ªÇкÒȰ¼º
  • alternative complement pathway
    º¸Ã¼´ëü°æ·Î, µµ¿òü´ëü°æ·Î
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • complement-fixing antibody
    µµ¿òü°áÇÕÇ×ü, º¸Ã¼°áÇÕÇ×ü
  • complement
    µµ¿òü, º¸Ã¼
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • complement-mediated
    µµ¿òü¸Å°³-
  • classic complement pathway
    º¸Ã¼ÀüÇüÀû°æ·Î, µµ¿òüÀüÇüÀû°æ·Î
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    µµ¿òü¼ººÐ
  • complement deficiency
    µµ¿òü°áÇÌ
  • complement fixation
    µµ¿òü°áÇÕ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivation of complement
    º¸Ã¼ºñµ¿È­.
  • Inactivation gate
    ºñȰ¼º °ü¹®(ÞªüÀàõ μڦ)
  • heat inactivation
    °¡¿­ºÒȰ¼ºÈ­, °¡¿­ºñµ¿È­
  • inactivation
    ºÒȰ¼ºÈ­.
  • inactivation
    ºÒȰ¼ºÈ­.
  • inactivation, heat
    °¡¿­ºÒȰ¼ºÈ­, °¡¿­ºñµ¿È­
  • insertional inactivation
    »ðÀÔ¼º À¯ÀüÀÚ ºñȰ¼º
  • photodynamic inactivation
    ±¤¿ªÇкñȰ¼º.
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • gonococcal complement fixation test
    ÀÓ±Õº¸Ã¼°áÇÕ¹ÝÀÀ°Ë»ç.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivation of complement
    º¸Ã¼ºñµ¿È­.
  • complement-induced = complement-mediated
    º¸Ã¼¸Å°³¼º
  • heat inactivation
    °¡¿­ºÒȰ¼ºÈ­, °¡¿­ºñµ¿È­
  • inactivation
    ºÒȰ¼ºÈ­.
  • inactivation
    ºÒȰ¼ºÈ­.
  • inactivation, heat
    °¡¿­ºÒȰ¼ºÈ­, °¡¿­ºñµ¿È­
  • insertional inactivation
    »ðÀÔ¼º À¯ÀüÀÚ ºñȰ¼º
  • photodynamic inactivation
    ±¤¿ªÇкñȰ¼º.
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • autoimmune complement fixation =AICF
    ÀÚ±â¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(¡­ÜÍô÷Ì¿ùêÚãëë).
  • autoimmune complement fixation =AICF
    ÀÚ°¡¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(¡­ÜÍô÷Ì¿ùêÚãëë).
  • autoimmune complement fixation =AICF
    ÀÚ±â¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(?ËÓ̧˭̰ËÑËô).
  • complement
    º¸Ã¼(ÜÍô÷), º¸Ãæ(ÜÍõö).
  • complement
    º¸Ã¼(ÜÍô÷)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catabolite inactivation
    īŸº¼¶óÀÌÆ® ºÒȰȭ(ÝÕüÀûù)
  • inactivation
    ºÒȰ¼ºÈ­(ÝÕüÀàõûù)
  • insertional inactivation
    »ðÀÔºÒȰ¼º(ߺìýÝÕüÀàõ)
  • photodynamic inactivation
    ±¤¿ªÇÐ ºÒȰ¼ºÈ­(ÝÕüÀàõûù)
  • thermal inactivation point
    ¿­ºÒȰ¼ºÈ­Á¡ (æðÝÕüÀàõûùïÃ)
  • autoimmune complement fixation
    ÀÚ°¡¸é¿ª (í»Ê«Øóæ¹) º¸Ã¼°íÁ¤ (ÜÍô÷ͳïÒ)
  • complement
    º¸Ã¼(ÜÍô÷)
  • complement activation
    º¸Ã¼ Ȱ¼ºÈ­(ÜÍô÷üÀàõûù)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • complement fixation
    º¸Ã¼°íÁ¤(ÜÍô÷ͳïÒ)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • complement fixation test
    º¸Ã¼°íÁ¤½ÃÇè(ÜÍô÷ͳïÒãËúÐ)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • indirect complement fixation test
    °£Á¢º¸Ã¼°íÁ¤½ÃÇè(ÊàïÈÜÍô÷ͳïÒãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivation
    ºÒȰ¼ºÈ­
  • complement
    º¸Ã¼, º¸Ãæ
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
KIU kallikrein inactivation unit
TIP thermal inactivation point; Toxicology Information Program; translation-inhibiting protein; tumor-in...
XIC X-inactivation center
XIST X-inactivation specific transcript
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CALI Chromophore assisted laser inactivation
KI Inactivation
XCI X chromosome inactivation
XCIP X chromosome inactivation pattern
XIC X inactivation center
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inactivation of complement
    º¸Ã¼ ºñµ¿È­
  • heat inactivation
    ¿­ ºÒȰ¼ºÈ­, ¿­ ºñµ¿È­
  • complement activation
    º¸Ã¼ Ȱ¼º ÀÛ¿ë, º¸Ã¼ Ȱ¼ºÈ­
  • complement consumption test
    º¸Ã¼ ¼Òºñ ½ÃÇè
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • complement fixation test
    º¸Ã¼ °áÇÕ ½ÃÇè, º¸Ã¼ °áÇÕ °Ë»ç, º¸Ã¼ °íÁ¤ °Ë»ç
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
  • complement splitting
    º¸Ã¼ ºÐÇØ
  • complement-mediated cytotoxicity
    º¸Ã¼ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • serum complement titer
    Ç÷û º¸Ã¼ °¡ÃøÁ¤
    ¸ðµç º¸Ã¼ Ȱ¼ºÀÇ ÃÑÇÕÀ¸·Î¼­ ÃøÁ¤µÈ´Ù.
  • treponema pallidum complement fixation test
    Æ®·¹Æ÷³×¸¶ º¸Ã¼ °áÇÕ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
radiation inactivation The technique of inactivating proteins in freeze dried (lyophilised) preparations using high energy particles (e.g. Electrons). One high energy particle can apparently inactivate all of the components of a multisubunit polypeptide, the method is therefore used to determine the molecular weight of functional oligomers.
(18 Nov 1997)
X inactivation <cell biology> The inactivation of one or other of each pair of X chromosomes to form the Barr body in female mammalian somatic cells.
Thus tissues whose original zygote carried heterozygous X borne genes should have individual cells expressing one or other but not both of the X borne gene products. The inactivation is thought to occur early in development and leads to mosaicism of expression of such genes in the body.
See: Lyon hypothesis.
(18 Nov 1997)
inactivation <neurology, physiology> For example of voltage gated sodium channels: process by which sodium channels that have been activated or opened by depolarisation subsequently close during the depolarisation. Distinguished from activation by its slower kinetics.
(18 Nov 1997)
insertional inactivation The inactivation of a gene due to the insertion of exogenous genetic material into that gene.
(14 Nov 1997)
enzyme inactivation The disappearance of an enzyme's activity during in vitro conditions, such as during a lab preparation of the enzyme, where the enzyme is exposed to conditions not normally found within its environment inside a living cell (like different pH, excess or too little salt, temperature changes, etc.)
(09 Oct 1997)
male chromosome complement The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes).
(12 Dec 1998)
genetic complement <biology, genetics> The set of chromosomes contained within any one particular cell.
(07 May 1998)
receptors, complement Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement.
(12 Dec 1998)
receptors, complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
(12 Dec 1998)
receptors, complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor.
(12 Dec 1998)
chromosome complement The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes.
(12 Dec 1998)
complement <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions.
Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9.
C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a.
The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules.
The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex.
Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors.
(05 Jan 1998)
complement 1 The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence.
(12 Dec 1998)
complement 1 inactivators Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily.
(12 Dec 1998)
complement 1q <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors.
Chemical name: Complement C1q
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivation
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í;º¸¿Ï¹°;¿©¼ö;¿©°¢;¿©È£;º¸ÃæÀ½Á¤;(ÇÊ¿äÇÑ)Àü¼ö;Àü·®;½Â¹«¿ø Á¤¿ø;º¸ÃæÇÏ¿© ¿ÏÀüÄÉÇÏ´Ù;º¸¿Ï(º¸Ãæ)ÇÏ´Ù;...ÀÇ º¸¿ÏÀÌ µÇ´Ù
  • complement fixation
    º¸Ã¼ °áÇÕ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á